Sanofi: favourable judgment for Praluent in US
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals announce that the Delaware District Court, in the United States, has ruled in their favour, dismissing all the claims of Amgen's patent relating to the antibodies targeting pcsk9, due to lack of assistance.
This decision has cancelled parts of the verdict previously made by a jury concerning the validity of three claims, which means that Sanofi and Regeneron have obtained the invalidation of Amgen's five patental claims.
The judgment therefore consolidates Praluent, which is jointly developed by Sanofi and Regeneron in a global collaboration arrangement. This product is approved in over 60 countries, including the United States, the European Union and Japan.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
This decision has cancelled parts of the verdict previously made by a jury concerning the validity of three claims, which means that Sanofi and Regeneron have obtained the invalidation of Amgen's five patental claims.
The judgment therefore consolidates Praluent, which is jointly developed by Sanofi and Regeneron in a global collaboration arrangement. This product is approved in over 60 countries, including the United States, the European Union and Japan.
Copyright (c) 2019 CercleFinance.com. All rights reserved.